Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-20
2006-06-20
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S211010, C514S211080, C514S212080, C514S218000, C514S222200, C514S222500, C514S274000, C514S316000, C514S319000, C514S321000, C544S129000, C544S315000, C546S187000, C546S188000, C546S205000, C546S206000
Reexamination Certificate
active
07064136
ABSTRACT:
A compound having the general formulaand methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
REFERENCES:
patent: 5521199 (1996-05-01), Jacobs et al.
patent: 5663179 (1997-09-01), Dumaitre et al.
patent: 5773620 (1998-06-01), Emonds-Alt et al.
patent: 5998444 (1999-12-01), Russell
patent: 6147083 (2000-11-01), Russell
patent: 6365602 (2002-04-01), Bernstein et al.
patent: 6500818 (2002-12-01), Bernstein et al.
patent: WO 0002859 (2000-01-01), None
patent: WO 0020003 (2000-04-01), None
patent: WO 0020389 (2000-04-01), None
patent: WO 0069438 (2000-11-01), None
Baker et al. “Use of NK1 receptor . . . ”CA 129:67787 (1998).
Culman et al, “Effect of Tachykinin Receptor Inhibition in the Brain on Cardiovascular and Behavioral Responses to Stress,” The Journal of Pharmacology and Experimental Therapeuics, vol. 280 (No. 1) p. 238-246 (Jun. 9, 1997).
AstraZeneca AB
Chang Celia
Mitchell Kenneth F.
LandOfFree
Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3628041